AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7637525 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric orthoses supplied to the experimental group
Number of subjects: 0
Study 7637525 — intervention group
Group type: COMPARATOR
Intervention: Control group (no podiatric orthoses)
Number of subjects: 0
Study 2566250 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.25 mg kg‐1)
Number of subjects: 20
Study 2566250 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (5 mg kg‐1)
Number of subjects: 20
Study 998556 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw wheat bran 12 g/day
Number of subjects: 10
Study 998556 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw wheat bran 20 g/day
Number of subjects: 10
Study 998556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked bran 13.2 g/day
Number of subjects: 10
Study 998556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked bran 22 g/day
Number of subjects: 10
Study 31836474 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 154
Study 31836474 — intervention group
Group type: COMPARATOR
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 154
Study 31601496 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenous, administered 1-42 days after chemoradiotherapy, then every 2 weeks up to 12 months)
Number of subjects: 713
Study 31601496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo administered 1-42 days after chemoradiotherapy, then every 2 weeks up to 12 months)
Number of subjects: 713
Study 27032655 — intervention group
Group type: EXPERIMENTAL
Intervention: About Face program plus Individual Placement and Support (AF+IPS)
Number of subjects: 84
Study 27032655 — intervention group
Group type: COMPARATOR
Intervention: About Face program (AF)
Number of subjects: 84
Study 25140956 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular blood transfusions
Number of subjects: 196
Study 25140956 — intervention group
Group type: COMPARATOR
Intervention: Standard care (observation)
Number of subjects: 196
Study 23529392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippophae rhamnoides
Number of subjects: 120
Study 23529392 — intervention group
Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 120
Study 23529392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippophae rhamnoides plus domperidone
Number of subjects: 120
Study 20947933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy
Number of subjects: 501
Study 20947933 — intervention group
Group type: COMPARATOR
Intervention: Manual aspiration catheter
Number of subjects: 501
Study 20947933 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy devices
Number of subjects: 501
Study 17627100 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted pressure-controlled ventilation (APCV)
Number of subjects: 34
Study 17627100 — intervention group
Group type: COMPARATOR
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 34
Study 17203750 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI plus systemic chemotherapy (HAI+SYC)
Number of subjects: 76
Study 17203750 — intervention group
Group type: COMPARATOR
Intervention: HAI
Number of subjects: 76
Study 14622075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral analysis system of psychotherapy (CBASP) with medication
Number of subjects: 367
Study 14622075 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral analysis system of psychotherapy (CBASP) alone
Number of subjects: 367
Study 10764306 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic PSV
Number of subjects: 10
Study 10764306 — intervention group
Group type: COMPARATOR
Intervention: Standard PSV
Number of subjects: 10
Study 8958493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 3 mg kg‐1
Number of subjects: 43
Study 8958493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 6 mg kg‐1
Number of subjects: 43
Study 8958493 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cola 0.2 mL kg‐1)
Number of subjects: 43
Study 7837987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffman's nipple stretching exercises
Number of subjects: 463
Study 7837987 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast shells
Number of subjects: 463
Study 7837987 — intervention group
Group type: COMPARATOR
Intervention: No Hoffman's exercises
Number of subjects: 463
Study 7837987 — intervention group
Group type: COMPARATOR
Intervention: No breast shells
Number of subjects: 463
Study 3293643 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine in 0.9% saline
Number of subjects: 0
Study 3293643 — intervention group
Group type: COMPARATOR
Intervention: diamorphine in 0.9% saline (0.5 mg in 15 ml)
Number of subjects: 0
Study 3293643 — intervention group
Group type: EXPERIMENTAL
Intervention: diamorphine mixed with 0.125% bupivacaine (0.5 mg in 15 ml)
Number of subjects: 0
Study 30903368 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (pelvic floor muscle exercises and self-management skills)
Number of subjects: 153
Study 30903368 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study 28566304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 51
Study 28566304 — intervention group
Group type: COMPARATOR
Intervention: CKD patients without HD
Number of subjects: 51
Study 28566304 — intervention group
Group type: EXPERIMENTAL
Intervention: All CKD patients
Number of subjects: 51
Study 29348380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seed extract 300 mg twice daily for 28 days
Number of subjects: 76
Study 29348380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23706428 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training with a CT surgeon or fellow on a low-fidelity task simulator
Number of subjects: 45
Study 23706428 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised training on a low-fidelity task simulator
Number of subjects: 45
Study 23706428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 45
Study 21849027 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) combined with treatment as usual
Number of subjects: 100
Study 21849027 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study 19022547 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard multivitamin containing high doses of folic acid and vitamins B(6) and B(12)
Number of subjects: 4110
Study 19022547 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 4110
Study 17252186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine during involved field radiotherapy, followed by six cycles of prednisone, lomustine, and vincristine
Number of subjects: 250
Study 17252186 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of 'eight-drugs-in-one-day' (8-in-1) chemotherapy followed by involved-field radiotherapy and six cycles of 8-in-1 chemotherapy
Number of subjects: 250
Study 17252186 — intervention group
Group type: COMPARATOR
Intervention: Institutional diagnosis of AMG
Number of subjects: 250
Study 17252186 — intervention group
Group type: COMPARATOR
Intervention: Institutional diagnosis of AO
Number of subjects: 250
Study 15016257 — intervention group
Group type: EXPERIMENTAL
Intervention: DOXY
Number of subjects: 10
Study 15016257 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRI
Number of subjects: 10
Study 12808771 — intervention group
Group type: COMPARATOR
Intervention: No fluid
Number of subjects: 18
Study 12808771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution
Number of subjects: 18
Study 12808771 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 18
Study 9000222 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypothalamic insufficiency
Number of subjects: 10
Study 9000222 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 10
Study 1732770 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic, low-osmolality radiocontrast agents
Number of subjects: 737
Study 1732770 — intervention group
Group type: COMPARATOR
Intervention: Ionic, high-osmolality radiocontrast agents
Number of subjects: 737
Study 1732770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 737
Study 6691786 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (2 micrograms/kg)
Number of subjects: 0
Study 6691786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily (QD)
Number of subjects: 2199
Study 31436835 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower weight
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower creatinine clearance
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation use prior to enrolment
Number of subjects: 2199
Study 31436835 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and heart failure
Number of subjects: 2199
Study 29893767 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive swallowing metrics (maximal tongue strength, hand grip strength, pharyngeal volume, age, body mass index, 3-oz water swallow challenge, 10-item Eating Assessment Tool, Frailty Index)
Number of subjects: 44
Study 29893767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal volume
Number of subjects: 44
Study 26915483 — intervention group
Group type: EXPERIMENTAL
Intervention: CUR 320 mg/day
Number of subjects: 101
Study 26915483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 24200201 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy enriched meals (standard texture; 315 kcal)
Number of subjects: 33
Study 24200201 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy enriched meals (texture modified; 303 kcal)
Number of subjects: 33
Study 24200201 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy enriched meals (standard texture)
Number of subjects: 33
Study 24200201 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy enriched meals (texture modified)
Number of subjects: 33
Study 24200201 — intervention group
Group type: COMPARATOR
Intervention: Texture modified meals
Number of subjects: 33
Study 21802222 — intervention group
Group type: EXPERIMENTAL
Intervention: Job Seekers' Workshop (JSW)
Number of subjects: 628
Study 21802222 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 628
Study 19569006 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided game (SSG) training
Number of subjects: 25
Study 19569006 — intervention group
Group type: COMPARATOR
Intervention: Generic training group (GTG)
Number of subjects: 25
Study 17289537 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered once monthly
Number of subjects: 0
Study 15362382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient odor (lavender, neroli) with relaxing suggestion
Number of subjects: 90
Study 15362382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient odor (lavender, neroli) with stimulating suggestion
Number of subjects: 90
Study 15362382 — intervention group
Group type: COMPARATOR
Intervention: Placebo with relaxing suggestion
Number of subjects: 90
Study 15362382 — intervention group
Group type: COMPARATOR
Intervention: Placebo with stimulating suggestion
Number of subjects: 90
Study 11434170 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II antigens typing in children with MCNS and glomerulosclerosis (progressive state from minimal lesions)
Number of subjects: 38
Study 11434170 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class II antigens typing in children with idiopathic FSGS
Number of subjects: 38
Study 11434170 — intervention group
Group type: COMPARATOR
Intervention: Control group (51 healthy unrelated individuals)
Number of subjects: 38
Study 14518297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (POF)
Number of subjects: 51
Study 14518297 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 51
Study 9663889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied at the catheter exit site (daily or three times per week)
Number of subjects: 181
Study 9663889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied at the catheter exit site
Number of subjects: 181
Study 2495214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free pelletized sodium cromoglycate (20 mg)
Number of subjects: 529
Study 2495214 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate plus lactose (20 mg)
Number of subjects: 529
Study 841307 — intervention group
Group type: COMPARATOR
Intervention: 10 mg cocaine hydrochloride intranasally
Number of subjects: 19
Study 841307 — intervention group
Group type: COMPARATOR
Intervention: 25 mg cocaine hydrochloride intranasally
Number of subjects: 19
Study 841307 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cocaine hydrochloride intranasally
Number of subjects: 19
Study 841307 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cocaine hydrochloride intravenously
Number of subjects: 19
Study 841307 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg cocaine hydrochloride intravenously
Number of subjects: 19
Study 31141505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment
Number of subjects: 3276
Study 29937865 — intervention group
Group type: EXPERIMENTAL
Intervention: ART/TB treatment arm
Number of subjects: 0
Study 29937865 — intervention group
Group type: COMPARATOR
Intervention: Withdrawing ART
Number of subjects: 0
Study 29937865 — intervention group
Group type: COMPARATOR
Intervention: TB alone treatment arm
Number of subjects: 0
Study 29937865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 0
Study 26426113 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacle ownership among migrant children needing glasses (147 of 640 children, 23.0%)
Number of subjects: 4409
Study 26426113 — intervention group
Group type: EXPERIMENTAL
Intervention: Having uncorrected visual acuity less than 6/18 in both eyes
Number of subjects: 4409
Study 23690688 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CPAP (4-15 mm H2O)
Number of subjects: 44
Study 23690688 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP (pressure 4 mm H2O)
Number of subjects: 44
Study 23690688 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment alone
Number of subjects: 44
Study 23690688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antihypertensive treatment with effective CPAP
Number of subjects: 44
Study 23690688 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with effective CPAP
Number of subjects: 44
Study 23690688 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment
Number of subjects: 44
Study 21950232 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol intravenously (Group A)
Number of subjects: 96
Study 21950232 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of 2% Lidocaine Hydrochloride into the fracture hematoma (Group B)
Number of subjects: 96
Study 19801055 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Pressure Management (TPM) strategy, 10 hours of treatment
Number of subjects: 37
Study 19801055 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 37
Study 16412737 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transfer of injected oocytes into two tubes
Number of subjects: 160
Study 16412737 — intervention group
Group type: COMPARATOR
Intervention: Unilateral transfer of injected oocytes into one tube
Number of subjects: 160
Study 15623179 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by minimally trained community counsellors for 4 weeks
Number of subjects: 366
Study 15623179 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by minimally trained community counsellors for 8 weeks
Number of subjects: 366
Study 15623179 — intervention group
Group type: COMPARATOR
Intervention: Control group (initially not counselled, later counselled for ethical reasons)
Number of subjects: 366
Study 11740134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 138
Study 11740134 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 138
Study 9002942 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (5 x 500 U/kg body weight intravenously over 14 days)
Number of subjects: 76
Study 9002942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously over 14 days)
Number of subjects: 76
Study 8097614 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 1110
Study 3316296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate chewing gum (5 mg per piece)
Number of subjects: 12
Study 3316296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate chewing gum with hydrogen peroxide releasing agent
Number of subjects: 12
Study 3316296 — intervention group
Group type: COMPARATOR
Intervention: Control gum (gum base with flavoring agents, no CHX or H2O2)
Number of subjects: 12
Study 30301557 — intervention group
Group type: COMPARATOR
Intervention: Group A (without preoperative fractured ankle CT scan)
Number of subjects: 51
Study 30301557 — intervention group
Group type: COMPARATOR
Intervention: Group B (with preoperative fractured CT scan)
Number of subjects: 51
Study 30301557 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (with preoperative bilateral ankle CT analysis)
Number of subjects: 51
Study 28410612 — intervention group
Group type: EXPERIMENTAL
Intervention: NoPALM formula
Number of subjects: 33
Study 28410612 — intervention group
Group type: COMPARATOR
Intervention: PALM formula
Number of subjects: 33
Study 28410612 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 33
Study 26044391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-derived urethane adhesive (Treatment group)
Number of subjects: 130
Study 26044391 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical drains)
Number of subjects: 130
Study 22884667 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga sessions (one-hour, three times a week from the 12th to the 28th week of gestation)
Number of subjects: 68
Study 22884667 — intervention group
Group type: COMPARATOR
Intervention: Conventional antenatal exercises (walking)
Number of subjects: 68
Study 20410465 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and Cued Selective Reminding Test (FCSRT)
Number of subjects: 1663
Study 19076089 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (I)
Number of subjects: 0
Study 19076089 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (V)
Number of subjects: 0
Study 19076089 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (A)
Number of subjects: 0
Study 15984585 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional mono mac therapy (20 mg twice a day)
Number of subjects: 60
Study 15984585 — intervention group
Group type: COMPARATOR
Intervention: Mono mac chronotherapy (10 to 20 mg 30 minutes before PMI episodes)
Number of subjects: 60
Study 12610046 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 at a dose of 1.5 pmol.kg(‐1)x min(‐1)
Number of subjects: 11
Study 12610046 — intervention group
Group type: COMPARATOR
Intervention: Control (no GLP-1)
Number of subjects: 11
Study 10496529 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-H gastric adenomas
Number of subjects: 223
Study 10496529 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-H gastric carcinomas
Number of subjects: 223
Study 10496529 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-L gastric adenomas
Number of subjects: 223
Study 10496529 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-L gastric carcinomas
Number of subjects: 223
Study 10496529 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameshift mutations in MSI-H tumors
Number of subjects: 223
Study 10496529 — intervention group
Group type: EXPERIMENTAL
Intervention: MSI-L tumors
Number of subjects: 223
Study 10496529 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mutations between MSI-H adenomas and MSI-H carcinomas
Number of subjects: 223
Study 8621746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg oral dose)
Number of subjects: 16
Study 8621746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1769410 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride (150-300 mg t.i.d.)
Number of subjects: 20
Study 1769410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1769410 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride
Number of subjects: 20
Study 7107102 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Anaerobic Threshold (IAT)
Number of subjects: 19
Study 7107102 — intervention group
Group type: COMPARATOR
Intervention: Fixed Anaerobic Threshold of 4 mmol.l(-1) lactate (ATc)
Number of subjects: 19
Study 31682026 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-L PEG, 4 h before VCE
Number of subjects: 410
Study 31682026 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-L PEG, 12 h before VCE
Number of subjects: 410
Study 31682026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L PEG, 12 h before VCE
Number of subjects: 410
Study 31682026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L PEG, 4 h before VCE
Number of subjects: 410
Study 31682026 — intervention group
Group type: COMPARATOR
Intervention: no PEG
Number of subjects: 410
Study 31682026 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-L PEG
Number of subjects: 410